CSIMarket
 
Transcode Therapeutics Inc   (NASDAQ: RNAZ)
 
Price: $1.6830 $-0.01 -0.414%
Day's High: $1.7100000381469727 Week Perf: -18.3 %
Day's Low: $ 1.63 30 Day Perf: -50.06 %
Volume (M): 5,769 52 Wk High: $ 20.99
Volume (M$): $ 0 52 Wk Avg: $8.11
Open: $1.68 52 Wk Low: $1.63



 Market Capitalization (Millions $) 16
 Shares Outstanding (Millions) 10
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -43
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Business Description


Transcode Therapeutics Inc is a biopharmaceutical company that specializes in the development of innovative RNA therapeutics. They focus on creating cutting-edge treatments for various diseases by harnessing the power of mRNA and related technologies.

Transcode Therapeutics utilizes its proprietary platform to design and optimize novel RNA therapeutics, including mRNA vaccines, mRNA-based gene therapies, and RNAi therapeutics. Their approach allows for precise targeting and modulation of disease-causing genes and proteins, offering potential solutions for a wide range of medical conditions.

The company aims to revolutionize the field of medicine by leveraging the versatility of RNA molecules to develop safe and effective therapies. Through their research and development efforts, Transcode Therapeutics is dedicated to advancing the understanding and application of RNA in the treatment of diseases, ultimately improving patient outcomes and quality of life.


   Company Address: 6 Liberty Square, #2382 Boston 2109 MA
   Company Phone Number: 837-3099   Stock Exchange / Ticker: NASDAQ RNAZ


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CORT        0.06% 
ONC   -4.87%    
OPK   -4.97%    
PFE   -4.46%    
RCUS   -16.64%    
SRPT   -11.2%    
• View Complete Report
   



Clinical Study

Harnessing microRNA TransCodes Pioneering Path Against Metastatic Cancer,

Published Thu, Oct 10 2024 11:00 AM UTC

Unlocking the Secrets of MicroRNA: TransCode Therapeutics Journey Toward Combatting Metastatic Cancer In the ever-evolving world of biotech innovation, TransCode Therapeutics is making bold strides with its groundbreaking microRNA-targeted technology. Their flagship candidate, TTX-MC138, is shining a promising light on the treatment of metastatic cancer. At the core of this...

Clinical Study

Pioneering Advances in RNA Therapeutics TransCode Therapeutics Initiates Phase 1 Clinical Trial for Novel Lead Cand...

Published Tue, Sep 17 2024 11:00 AM UTC

: TransCode Therapeutics has announced the successful initiation of its Phase 1 clinical trial, marking a significant milestone in the field of RNA-based therapeutics. This trial explores the safety and efficacy of the company’s first-in-class lead therapeutic candidate, TTX-MC138, designed for the treatment of cancer that expresses miR-10b. This article discusses the imp...

Clinical Study

Disrupting Metastasis TransCode Therapeutics TTX-MC138 Paves a New Path in Cancer Treatment with Unpreced...

Published Tue, Sep 10 2024 11:00 AM UTC

TransCode Therapeutics, an innovative biotech company, has recently announced the publication of several pivotal studies revealing the profound potential of its lead therapeutic candidate, TTX-MC138, in combating metastatic cancer. These synergistic findings underscore both the significant preclinical efficacy and promising clinical outcomes associated with TTX-MC138, alongs...

Clinical Study

Navigating Challenges and Opportunities TransCode Therapeutics Secures $2 Million NIH Grant Amid Financia...

Published Thu, Sep 5 2024 11:00 AM UTC

TransCode Therapeutics Inc. a clinical-stage biopharmaceutical company focusing on developing RNA-targeted therapeutics for cancer treatment, has recently been awarded a $2 million grant from the National Institutes of Health (NIH). This grant is intended to support the clinical evaluation of TransCode s lead candidate, TTX-MC138, an innovative RNAi-based therapy designed to...

Shares

TransCode Therapeutics Secures Funding for RNA Oncology Treatments: Impact on Shareholders and Financials

Published Wed, Jul 24 2024 8:05 PM UTC

TransCode Therapeutics Continues to Secure Funding for Innovative RNA Oncology Treatments: Impact on Shareholders and Financials
In recent news, TransCode Therapeutics, a clinical-stage RNA oncology company, has made significant strides in securing funding for their innovative treatments. With a series of successful financial offerings, including a $1.2 million registere...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.3
Working Capital Ratio 1.94
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -56.1 $
Revenues (TTM) -
Cash Flow (TTM) 0.57 $
Cash 0.88 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -3,569,530
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.